Livzon Pharmaceutical Group Inc.
General ticker "LVZPF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $3.4B (TTM average)
Livzon Pharmaceutical Group Inc. follows the US Stock Market performance with the rate: 39.8%.
Estimated limits based on current volatility of 0.0%: low 5.22$, high 5.22$
Factors to consider:
- Company pays dividends (irregularly): last record date 2025-06-16, amount 0.15$ (Y2.87%)
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.97$, 4.63$]
- 2025-12-31 to 2026-12-31 estimated range: [3.01$, 4.72$]
Financial Metrics affecting the LVZPF estimates:
- Positive: with PPE of 11.1 at the end of fiscal year the price was very low
- Positive: Operating profit margin, % of 24.08 > 18.64
- Negative: negative Industry operating cash flow (median)
- Positive: 6.82 < Operating cash flow per share per price, % of 12.94
- Negative: negative Industry operating income (median)
- Positive: Return on assets ratio (scaled to [-100,100]) of 8.61 > 6.04
- Positive: Interest expense per share per price, % of 0.38 <= 0.79
Short-term LVZPF quotes
Long-term LVZPF plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | CNY12,629.58MM | CNY12,430.04MM | CNY11,812.34MM |
| Operating Expenses | CNY10,279.02MM | CNY10,014.93MM | CNY8,967.94MM |
| Operating Income | CNY2,350.56MM | CNY2,415.11MM | CNY2,844.40MM |
| Non-Operating Income | CNY-20.01MM | CNY-32.44MM | CNY-38.25MM |
| Interest Expense | CNY97.55MM | CNY102.09MM | CNY88.61MM |
| R&D Expense | CNY1,426.52MM | CNY1,334.70MM | CNY1,033.36MM |
| Income(Loss) | CNY2,330.55MM | CNY2,382.67MM | CNY2,806.15MM |
| Taxes | CNY375.01MM | CNY485.07MM | CNY501.66MM |
| Profit(Loss)* | CNY1,909.41MM | CNY1,953.65MM | CNY2,061.10MM |
| Stockholders Equity | CNY13,876.02MM | CNY14,042.50MM | CNY13,862.33MM |
| Inventory | CNY2,045.34MM | CNY2,060.65MM | CNY1,997.64MM |
| Assets | CNY24,864.83MM | CNY25,044.83MM | CNY24,455.83MM |
| Operating Cash Flow | CNY2,772.67MM | CNY3,394.20MM | CNY2,978.85MM |
| Capital expenditure | CNY940.15MM | CNY820.45MM | CNY570.16MM |
| Investing Cash Flow | CNY-1,229.87MM | CNY-777.11MM | CNY-660.33MM |
| Financing Cash Flow | CNY-720.36MM | CNY-1,733.41MM | CNY-2,485.88MM |
| Earnings Per Share** | CNY2.04 | CNY2.10 | CNY2.24 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.